GACVS held its fourteenth meeting in Geneva, Switzerland, on 6-7 June 2006.2.
GACVS于2006年6月6 - 7日在瑞士日内瓦召开了第14次会议。
GACVS held its fifteenth meeting in Geneva, Switzerland, on 29-30 November 2006.2.
GACVS于2006年11月29 - 30日在瑞士日内瓦召开了第15次会议。
The GACVS might collate such information, which should be evaluated and made widely available.
GACVS可负责整理此类信息，对其进行评估并使更多的人可以获得这些信息。
GACVS considered safety issues pertaining to the poliomyelitis eradication programme worldwide.
GACVS审议了有关全球范围内正在开展的“消灭脊髓灰质炎规划”的安全性问题。
Studies on the latter group would be difficult to conduct, but the GACVS encourages further research.
在这些婴儿中开展研究比较困难，但GACVS鼓励在这方面开展进一步的研究。
The GACVS will continue to review the evidence, including any epidemiological data, that might emerge from on-going studies.
GACVS将继续审阅从正在开展的研究中获得的相关证据（包括任何流行病学资料）。
A working subgroup of 6 GACVS members was formed to ensure that the initiative continues to move forward in a timely fashion.
已组建了一支由6名GACVS成员组成的工作小组，以确保该倡议能继续及时地取得进展。
GACVS recommended that future immunization campaigns should be accompanied by strengthened AEFI monitoring and investigation activities.
GACVS建议今后开展强化免疫时应该同时加强AEFI监测和病历调查工作。
These points, taken together, lead GACVS to conclude that the paper provides insufficient evidence to warrant changes to public health policy.
综上所述，GACVS得出结论认为：该论文提供的证据不足，没有理由要改变目前的公共卫生政策。
Expert advice and data presented to the GACVS in June 2002 indicate that the pharmacokinetics of ethyl and methyl mercury are quite different.
专家咨询和2002年6月GACVS的会议资料表明，乙基汞与甲基汞的药物代谢动力学情况是很不一样的。
GACVS held its ninth meeting in Geneva, Switzerland, on 3-4 December 2003 and considered the following safety concerns regarding immunization.2.
GACVS于2003年12月3 - 4日在瑞士日内瓦召开了第九次会议，审议了以下有关免疫接种的安全性问题。
GACVS considered recent data on the safety profile of live attenuated sa 14-14-2 JE vaccine, provided in a number of expert presentations to the Committee.
GACVS审议了一系列新近由专家递交的关于乙脑病毒减毒活疫苗SA14 - 14 - 2株安全特性的资料。
On that basis the GACVS considers that pharmacokinetic and developmental studies undertaken do not support concerns over the safety of thiomersal in vaccines.
基于此，全球疫苗安全咨询委员会认为，所开展的药动学与发育研究不能支持对疫苗中硫柳汞安全性的担忧。
Expert consultation and data presented to GACVS indicate that the pharmacokinetic profile of ethyl mercury is substantially different to that of methyl mercury.
专家协商以及向全球疫苗安全咨询委员会提供的数据显示，乙基汞的药动学特征与甲基汞存有实质性区别。
Expert consultation and data presented to the GACVS indicate that the pharmacokinetic profile of ethyl mercury is substantially different from that of methyl mercury.
提交给GACVS的专家咨询意见和资料表明，甲基汞和乙基汞在药物动力学方面截然不同。
A subgroup of GACVS will be formed to pursue this goal in connection with the series of WHO regulatory preparedness workshops on human vaccines for pandemic influenza.
GACVS将组建一个工作小组努力完成这一目标。该小组将结合一系列世界卫生组织人用大流行性流感疫苗管理预案研讨会开展工作。
GACVS supports the -recent WHO initiative to further characterize BCG strains, which will help systematic differentiation of BCG vaccines in terms of safety and efficacy.
GACVS赞同世卫组织最近发出的关于进一步确定bcg株特性的倡议，认为此项工作将有助于从安全性和有效性出发、对BCG疫苗进行系统的鉴别。
GACVS is not aware of any safety issues that would restrict the provision of a rubella-containing combination vaccine in place of single rubella vaccine in those circumstances.
GACVS尚不清楚在上述情况下提供含风疹的联合疫苗来代替单价风疹疫苗是否存在可能会限制联合疫苗使用的安全性问题。
At its request, GACVS was presented with historical experience from the 1976 swine influenza a (H1N1) outbreak and vaccination efforts initiated at the time in the United States.
应GACVS要求，会议介绍了有关1976年猪流感a型病毒(H1N1)暴发和美国当时启动的疫苗接种工作的历史经验。
GACVS was informed of the programme's decision to stop oral polio vaccine use after certification of eradication in light of the adverse effects associated with its long-term use.
GACVS获悉，鉴于长期使用口服脊髓灰质炎疫苗可伴有不良反应，消灭脊髓灰质炎规划已经决定，在证实消灭脊髓灰质炎之后，停止使用该口服疫苗。
GACVS considered that it would be important to examine the possibility that naturally circulating yellow fever virus in endemic regions may account for some of these differences in risk.
在疫区自然传播的黄热病病毒可能导致这些危险性差异，GACVS认为，对这种可能性的研究非常重要。
At previous meetings3, 4, the GACVS requested that global vaccine pharmacovigilance be strengthened, particularly within the context of the WHO Programme for International Drug Monitoring.
在以前的一些会议34上，GACVS要求加强全球疫苗药物警戒，特别是在世卫组织国际药物监测合作计划的背景下开展工作。
Two expert reports on the safety of smallpox vaccines were presented to the Global Advisory Committee on vaccine safety (GACVS) at its eighth meeting in Geneva, Switzerland on June 11-12, 2003.
2003年6月11 - 12日，全球疫苗安全咨询委员会(GACVS)于瑞士日内瓦举行了第8次会议。会议有两份关于天花疫苗安全性的专家报告。
The GACVS acknowledges that supposed "immune overload" as a result of infant immunization is a parental and societal concern that may limit confidence in and thus affect immunization programmes.
GACVS承认，所谓“免疫超负荷”(immune overload)作为婴儿免疫接种的结果，是由于父母和社会对其高度关注所致，可能会因此降低对免疫接种规划的信赖，进而影响免疫规划的开展。
On the basis of the foregoing, the GACVS concluded that the most recent pharmacokinetic and developmental studies do not support concerns over the safety of thiomersal (ethyl mercury) in vaccines.
基于以上所述，GACVS得出结论认为，最近的药代动力学和发育学研究结果并不支持疫苗所含硫柳汞(乙基汞)存在安全性问题的说法。
The GACVS recommended that to further understand MMF, additional research studies needed to be undertaken to evaluate the clinical, epidemiological, immunological and basic science aspects of MMF.
GACVS建议，为了进一步了解MMF，需要开展对MMF的临床、流行病学、免疫学和基础医学等方面的进一步研究。
An updated account of the safety of smallpox vaccination, was presented to the Global Advisory Committee on Vaccine safety (GACVS) at its ninth meeting in Geneva, Switzerland on December 3-4, 2003.
2003年12月3 - 4日，全球疫苗安全咨询委员会(GACVS)第九次会议在瑞士日内瓦举行。会议期间，一份关于天花免疫接种安全性问题的报告被提交给GACVS。
As a result of the above-mentioned request, a subgroup of 6 GACVS members was formed to work closely with the secretariat to ensure that the initiative continues to move forward in a timely fashion.4.
基于以上要求，由6名GACVS成员组成一个小组，与秘书处密切合作开展工作，以保证该项行动能及时推进。
As a result of the above-mentioned request, a subgroup of 6 GACVS members was formed to work closely with the secretariat to ensure that the initiative continues to move forward in a timely fashion.4.
基于以上要求，由6名GACVS成员组成一个小组，与秘书处密切合作开展工作，以保证该项行动能及时推进。
应用推荐